Premium
Premium statistics

Industry-specific and extensively researched technical data (partially from exclusive partnerships).

A paid subscription is required for full access.

Top 20 neurology products in the U.S. based on revenue in 2016 (in million U.S. dollars)*

Exclusive Premium Statistic

Revenue of top 20 neurology products in the U.S. 2016 This statistic displays the projected top 20 products for neurology diseases based on revenue in the United States during 2016. In that year, Abilify, an Otsuka product, is expected to generate approximately 322 million U.S. dollars in revenues, a decrease of some 1.7 billion dollars compared to 2014, caused by patent loss.
Show more
Exclusive Premium statistic

Get a Premium Account for unrestrained access.
Benefits of our Premium membership:

  • Access to all Premium statistics
  • Download as XLS, PNG and PDF
  • Detailed source and background information
Premium Account
$49 per month*
(billed annually)
*Single license

Access to this and all other statistics on 80,000 topics from

$588 / Year

View price details

Product name (company)Revenue in million U.S. dollars
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
Product name (company)Revenue in million U.S. dollars
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
Exclusive Premium statistic

Get a Premium Account for unrestrained access.
Benefits of our Premium membership:

  • Access to all Premium statistics
  • Download as XLS, PNG and PDF
  • Detailed source and background information
Premium Account
$49 per month*
(billed annually)
*Single license

Access to this and all other statistics on 80,000 topics from

$588 / Year

View price details

© Statista 2018

Download Settings Share
Chart type
Datalabels
Share on Social Media
Download started
Please be patient - this may take a moment
Description Source More information
This statistic displays the projected top 20 products for neurology diseases based on revenue in the United States during 2016. In that year, Abilify, an Otsuka product, is expected to generate approximately 322 million U.S. dollars in revenues, a decrease of some 1.7 billion dollars compared to 2014, caused by patent loss.
Show more
Release date
October 2016
Region
United States
Survey time period
as of October 2016
Supplementary notes
* All values are projected. The original list inlcudes products FDA indicates as approved for treatimg MS, Parkinson's disease, Alzheimer's disease, depression, schizophrenia, bipolar and insomnia.

Statista Accounts: Access All Statistics. Starting from $588 / Year

Leading companies trust Statista:

Related Studies: Available to Download in PDF or PPTX Format

Pharmaceutical brands: Abilify (BMS/Otsuka)

All Information
in one Presentation

Pharmaceutical brands: Abilify (BMS/Otsuka)

Everything On "Pharmaceutical brands: Abilify (BMS/Otsuka)" in One Document: Edited and Divided into Handy Chapters. Including Detailed References.

Other Reports & Dossiers
Statista has been my savior on several occasions. The site is easy to maneuver and the data is in a format that can go right into a report or presentation.
Marlene Greenfield

Marlene Greenfield
Vice President, Hearst Magazines

Statistics on "Pharmaceutical brands: Abilify (BMS/Otsuka)"

  • Overview
  • Drug prices and consumer behavior
  • Advertising expenditures
Statista for your company

Saves time and money: instant access to this and 1 million more statistics.
Access to dossiers, industry reports and many other studies.

Need help with using Statista for your research? Tutorials and first steps

Further Content: Statistics, Studies, and Topic Pages

Statistics on the topic

Topics

About Statista

Learn more about how Statista can support your business.

Request webinar
Do you have any questions about our business solutions?

We provide you with detailed information about our Corporate Account.